Reviewer’s report

Title: Predictors of patient satisfaction with antipsychotic medication in schizophrenia: Data from a randomized double-blind trial

Version: 1 Date: 8 July 2006

Reviewer: René Kahn

Reviewer’s report:

This is a well-written and interesting report examining the relationship between treatment satisfaction and various outcomes (such as compliance, efficacy) from a dataset derived from a 6 week randomized clinical trial comparing risperidone, quetiapine and placebo. Satisfaction was measured after 2 and 6 weeks in the study using a one item scale.

The measurement of patient satisfaction hardly takes place in RDC’s and this is a major omission. Therefore the authors should be praised for examining this important issue. That they use a placebo controlled RDC for that purpose and use a single item scale instead of lengthy and cumbersome scales as are too often used, makes the study even more appealing. The results are important since they show that pt satisfaction is directly linked to symptoms improvement in psychotic symptoms and to compliance as well. This sheds important light on the underpinnings on efficacy and compliance.

It would be helpful if the authors also include a table of pt satisfaction and outcomes at day 42 and improve figure 1 which is incomprehensible (probably because it lack legends for the X and Y axes. Fig 2 can be deleted, it is not instructive.

What next?: Accept after minor essential revisions

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No

Declaration of competing interests:

I have received speakers and consulting fees from both Johnson and Johnson and AstraZeneca. I own stock in JNJ.